ID   ARI1B_HUMAN             Reviewed;        2319 AA.
AC   Q8NFD5; Q5JRD1; Q5VYC4; Q8IZY8; Q8TEV0; Q8TF02; Q99491; Q9ULI5;
DT   30-AUG-2005, integrated into UniProtKB/Swiss-Prot.
DT   25-MAY-2022, sequence version 3.
DT   28-JUN-2023, entry version 192.
DE   RecName: Full=AT-rich interactive domain-containing protein 1B {ECO:0000305};
DE            Short=ARID domain-containing protein 1B;
DE   AltName: Full=BRG1-associated factor 250b;
DE            Short=BAF250B;
DE   AltName: Full=BRG1-binding protein hELD/OSA1;
DE   AltName: Full=Osa homolog 2;
DE            Short=hOsa2;
DE   AltName: Full=p250R;
GN   Name=ARID1B {ECO:0000312|HGNC:HGNC:18040};
GN   Synonyms=BAF250B, DAN15, KIAA1235, OSA2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-597 (ISOFORM 5).
RX   PubMed=9804814; DOI=10.1074/jbc.273.46.30466;
RA   Mangel L., Ternes T., Schmitz B., Doerfler W.;
RT   "New 5'-(CGG)-3' repeats in the human genome.";
RL   J. Biol. Chem. 273:30466-30471(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 92-281.
RX   PubMed=8896557; DOI=10.1038/ng1196-285;
RA   Imbert G., Saudou F., Yvert G., Devys D., Trottier Y., Garnier J.-M.,
RA   Weber C., Mandel J.-L., Cancel G., Abbas N., Duerr A., Didierjean O.,
RA   Stevanin G., Agid Y., Brice A.;
RT   "Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high
RT   sensitivity to expanded CAG/glutamine repeats.";
RL   Nat. Genet. 14:285-291(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 155-2319 (ISOFORM 5), TISSUE SPECIFICITY,
RP   INTERACTION WITH SMARCA2 AND SMARCA4, AND IDENTIFICATION IN A SWI/SNF-LIKE
RP   COMPLEX WITH ARID1A.
RX   PubMed=12200431; DOI=10.1074/jbc.m205961200;
RA   Inoue H., Furukawa T., Giannakopoulos S., Zhou S., King D.S., Tanese N.;
RT   "Largest subunits of the human SWI/SNF chromatin-remodeling complex promote
RT   transcriptional activation by steroid hormone receptors.";
RL   J. Biol. Chem. 277:41674-41685(2002).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 353-2319 (ISOFORM 5), TISSUE SPECIFICITY,
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND IDENTIFICATION IN A SWI/SNF-LIKE
RP   EBAFB COMPLEX.
RX   PubMed=12665591; DOI=10.1128/mcb.23.8.2942-2952.2003;
RA   Nie Z., Yan Z., Chen E.H., Sechi S., Ling C., Zhou S., Xue Y., Yang D.,
RA   Murray D., Kanakubo E., Cleary M.L., Wang W.;
RT   "Novel SWI/SNF chromatin-remodeling complexes contain a mixed-lineage
RT   leukemia chromosomal translocation partner.";
RL   Mol. Cell. Biol. 23:2942-2952(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 574-2319 (ISOFORM 2), SUBCELLULAR LOCATION,
RP   TISSUE SPECIFICITY, INTERACTION WITH SMARCA4, IDENTIFICATION IN A COMPLEX
RP   WITH SMARCA4 AND SMARCD1, AND IDENTIFICATION IN A SWI/SNF-LIKE COMPLEX WITH
RP   ARID1A.
RX   PubMed=11988099; DOI=10.1042/bj3640255;
RA   Hurlstone A.F., Olave I.A., Barker N., van Noort M., Clevers H.;
RT   "Cloning and characterization of hELD/OSA1, a novel BRG1 interacting
RT   protein.";
RL   Biochem. J. 364:255-264(2002).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 788-2319 (ISOFORM 5), AND IDENTIFICATION IN
RP   SWI/SNF COMPLEXES.
RC   TISSUE=Brain;
RX   PubMed=11734557; DOI=10.1074/jbc.m108702200;
RA   Kato H., Tjernberg A., Zhang W., Krutchinsky A.N., An W., Takeuchi T.,
RA   Ohtsuki Y., Sugano S., de Bruijn D.R., Chait B.T., Roeder R.G.;
RT   "SYT associates with human SNF/SWI complexes and the C-terminal region of
RT   its fusion partner SSX1 targets histones.";
RL   J. Biol. Chem. 277:5498-5505(2002).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 888-2319 (ISOFORM 3).
RC   TISSUE=Brain;
RX   PubMed=10574462; DOI=10.1093/dnares/6.5.337;
RA   Nagase T., Ishikawa K., Kikuno R., Hirosawa M., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XV. The
RT   complete sequences of 100 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 6:337-345(1999).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-599; SER-1638 AND SER-1642,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [10]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2 (ISOFORM 1), CLEAVAGE OF
RP   INITIATOR METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [12]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-1860, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1638 AND SER-1642, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1638 AND SER-1798, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [15]
RP   INVOLVEMENT IN CSS1, AND VARIANTS ALA-94 INS; 128-ALA--ALA-130 DEL;
RP   HIS-165; SER-329; 401-GLY-GLY-402 DEL; GLY-402 DEL; 410-GLY-GLY-411 DEL;
RP   416-GLY--GLY-420 DEL; VAL-446; ALA-479; VAL-512; PRO-533 INS; ASN-580;
RP   THR-614; GLU-959; LEU-1063; ILE-1175; PRO-1332; GLU-1354; ARG-1386;
RP   ASN-1404; SER-1494; LYS-1549; HIS-1589; MET-1656; SER-1742; GLU-1816 DEL;
RP   ARG-1856; ASN-1934; ARG-1981; ARG-2037 AND ARG-2246.
RX   PubMed=22405089; DOI=10.1016/j.ajhg.2012.02.007;
RA   Hoyer J., Ekici A.B., Endele S., Popp B., Zweier C., Wiesener A.,
RA   Wohlleber E., Dufke A., Rossier E., Petsch C., Zweier M., Gohring I.,
RA   Zink A.M., Rappold G., Schrock E., Wieczorek D., Riess O., Engels H.,
RA   Rauch A., Reis A.;
RT   "Haploinsufficiency of ARID1B, a member of the SWI/SNF-a chromatin-
RT   remodeling complex, is a frequent cause of intellectual disability.";
RL   Am. J. Hum. Genet. 90:565-572(2012).
RN   [16]
RP   INVOLVEMENT IN CSS1.
RX   PubMed=22426308; DOI=10.1038/ng.2219;
RA   Tsurusaki Y., Okamoto N., Ohashi H., Kosho T., Imai Y., Hibi-Ko Y.,
RA   Kaname T., Naritomi K., Kawame H., Wakui K., Fukushima Y., Homma T.,
RA   Kato M., Hiraki Y., Yamagata T., Yano S., Mizuno S., Sakazume S., Ishii T.,
RA   Nagai T., Shiina M., Ogata K., Ohta T., Niikawa N., Miyatake S., Okada I.,
RA   Mizuguchi T., Doi H., Saitsu H., Miyake N., Matsumoto N.;
RT   "Mutations affecting components of the SWI/SNF complex cause Coffin-Siris
RT   syndrome.";
RL   Nat. Genet. 44:376-378(2012).
RN   [17]
RP   INVOLVEMENT IN CSS1.
RX   PubMed=22426309; DOI=10.1038/ng.2217;
RA   Santen G.W., Aten E., Sun Y., Almomani R., Gilissen C., Nielsen M.,
RA   Kant S.G., Snoeck I.N., Peeters E.A., Hilhorst-Hofstee Y., Wessels M.W.,
RA   den Hollander N.S., Ruivenkamp C.A., van Ommen G.J., Breuning M.H.,
RA   den Dunnen J.T., van Haeringen A., Kriek M.;
RT   "Mutations in SWI/SNF chromatin remodeling complex gene ARID1B cause
RT   Coffin-Siris syndrome.";
RL   Nat. Genet. 44:379-380(2012).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-585; SER-599; SER-1625;
RP   SER-1638 AND SER-1642, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [20]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT ARG-640, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.o113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M.,
RA   Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V.,
RA   Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [21]
RP   REVIEW ON SWI/SNF CHROMATIN REMODELING COMPLEXES.
RX   PubMed=12672490; DOI=10.1016/s0959-437x(03)00022-4;
RA   Martens J.A., Winston F.;
RT   "Recent advances in understanding chromatin remodeling by SWI/SNF
RT   complexes.";
RL   Curr. Opin. Genet. Dev. 13:136-142(2003).
RN   [22]
RP   DNA-BINDING, IDENTIFICATION IN SWI/SNF COMPLEXES, AND INTERACTION WITH
RP   SMARCA2; SMARCA4 AND SMARCC1.
RX   PubMed=15170388; DOI=10.1042/bj20040524;
RA   Wang X., Nagl N.G., Wilsker D., Van Scoy M., Pacchione S., Yaciuk P.,
RA   Dallas P.B., Moran E.;
RT   "Two related ARID family proteins are alternative subunits of human SWI/SNF
RT   complexes.";
RL   Biochem. J. 383:319-325(2004).
RN   [23]
RP   DNA-BINDING.
RX   PubMed=14982958; DOI=10.1093/nar/gkh277;
RA   Wilsker D., Patsialou A., Zumbrun S.D., Kim S., Chen Y., Dallas P.B.,
RA   Moran E.;
RT   "The DNA-binding properties of the ARID-containing subunits of yeast and
RT   mammalian SWI/SNF complexes.";
RL   Nucleic Acids Res. 32:1345-1353(2004).
RN   [24]
RP   IDENTIFICATION IN THE BAF COMPLEX, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=18765789; DOI=10.1101/gad.471408;
RA   Lange M., Kaynak B., Forster U.B., Toenjes M., Fischer J.J., Grimm C.,
RA   Schlesinger J., Just S., Dunkel I., Krueger T., Mebus S., Lehrach H.,
RA   Lurz R., Gobom J., Rottbauer W., Abdelilah-Seyfried S., Sperling S.;
RT   "Regulation of muscle development by DPF3, a novel histone acetylation and
RT   methylation reader of the BAF chromatin remodeling complex.";
RL   Genes Dev. 22:2370-2384(2008).
RN   [25]
RP   REVIEW ON SWI/SNF CHROMATIN REMODELING COMPLEXES.
RX   PubMed=22952240; DOI=10.1074/jbc.r111.309302;
RA   Euskirchen G., Auerbach R.K., Snyder M.;
RT   "SWI/SNF chromatin-remodeling factors: multiscale analyses and diverse
RT   functions.";
RL   J. Biol. Chem. 287:30897-30905(2012).
RN   [26]
RP   REVIEW ON SWI/SNF CHROMATIN REMODELING COMPLEXES.
RX   PubMed=26601204; DOI=10.1126/sciadv.1500447;
RA   Kadoch C., Crabtree G.R.;
RT   "Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic
RT   insights gained from human genomics.";
RL   Sci. Adv. 1:E1500447-E1500447(2015).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 1124-1242.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Crystal structure of the HBAF250B AT-rich interaction domain (ARID).";
RL   Submitted (OCT-2006) to the PDB data bank.
RN   [28]
RP   VARIANT [LARGE SCALE ANALYSIS] ALA-897.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
RN   [29]
RP   VARIANTS LEU-854; ALA-1519; LEU-1646 AND TYR-2070.
RX   PubMed=26376624; DOI=10.1186/s12864-015-1898-1;
RA   Yu Y., Yao R., Wang L., Fan Y., Huang X., Hirschhorn J., Dauber A.,
RA   Shen Y.;
RT   "De novo mutations in ARID1B associated with both syndromic and non-
RT   syndromic short stature.";
RL   BMC Genomics 16:701-701(2015).
RN   [30]
RP   VARIANTS ARG-571 AND SER-1496.
RX   PubMed=26637798; DOI=10.1016/j.neuron.2015.11.009;
RA   D'Gama A.M., Pochareddy S., Li M., Jamuar S.S., Reiff R.E., Lam A.T.,
RA   Sestan N., Walsh C.A.;
RT   "Targeted DNA Sequencing from Autism Spectrum Disorder Brains Implicates
RT   Multiple Genetic Mechanisms.";
RL   Neuron 88:910-917(2015).
CC   -!- FUNCTION: Involved in transcriptional activation and repression of
CC       select genes by chromatin remodeling (alteration of DNA-nucleosome
CC       topology). Component of SWI/SNF chromatin remodeling complexes that
CC       carry out key enzymatic activities, changing chromatin structure by
CC       altering DNA-histone contacts within a nucleosome in an ATP-dependent
CC       manner. Belongs to the neural progenitors-specific chromatin remodeling
CC       complex (npBAF complex) and the neuron-specific chromatin remodeling
CC       complex (nBAF complex). During neural development a switch from a
CC       stem/progenitor to a postmitotic chromatin remodeling mechanism occurs
CC       as neurons exit the cell cycle and become committed to their adult
CC       state. The transition from proliferating neural stem/progenitor cells
CC       to postmitotic neurons requires a switch in subunit composition of the
CC       npBAF and nBAF complexes. As neural progenitors exit mitosis and
CC       differentiate into neurons, npBAF complexes which contain ACTL6A/BAF53A
CC       and PHF10/BAF45A, are exchanged for homologous alternative
CC       ACTL6B/BAF53B and DPF1/BAF45B or DPF3/BAF45C subunits in neuron-
CC       specific complexes (nBAF). The npBAF complex is essential for the self-
CC       renewal/proliferative capacity of the multipotent neural stem cells.
CC       The nBAF complex along with CREST plays a role regulating the activity
CC       of genes essential for dendrite growth (By similarity). Binds DNA non-
CC       specifically (PubMed:14982958, PubMed:15170388).
CC       {ECO:0000250|UniProtKB:E9Q4N7, ECO:0000269|PubMed:14982958,
CC       ECO:0000269|PubMed:15170388, ECO:0000303|PubMed:12672490,
CC       ECO:0000303|PubMed:22952240, ECO:0000303|PubMed:26601204}.
CC   -!- SUBUNIT: Component of SWI/SNF chromatin remodeling complexes, in some
CC       of which it can be mutually exclusive with ARID1B/BAF250B
CC       (PubMed:12672490, PubMed:22952240, PubMed:26601204, PubMed:12200431,
CC       PubMed:11988099, PubMed:15170388). The canonical complex contains a
CC       catalytic subunit (either SMARCA4/BRG1/BAF190A or SMARCA2/BRM/BAF190B)
CC       and at least SMARCE1, ACTL6A/BAF53, SMARCC1/BAF155, SMARCC2/BAF170, and
CC       SMARCB1/SNF5/BAF47. Other subunits specific to each of the complexes
CC       may also be present permitting several possible combinations
CC       developmentally and tissue specific (PubMed:11734557, PubMed:22952240,
CC       PubMed:26601204). Component of the BAF (SWI/SNF-A) complex, which
CC       includes at least actin (ACTB), ARID1A/BAF250A, ARID1B/BAF250B,
CC       SMARCA2/BRM, SMARCA4/BRG1/BAF190A, ACTL6A/BAF53, ACTL6B/BAF53B,
CC       SMARCE1/BAF57, SMARCC1/BAF155, SMARCC2/BAF170, SMARCB1/SNF5/INI1, and
CC       one or more SMARCD1/BAF60A, SMARCD2/BAF60B, or SMARCD3/BAF60C
CC       (PubMed:18765789). In muscle cells, the BAF complex also contains DPF3.
CC       Component of neural progenitors-specific chromatin remodeling complex
CC       (npBAF complex) composed of at least, ARID1A/BAF250A or ARID1B/BAF250B,
CC       SMARCD1/BAF60A, SMARCD3/BAF60C, SMARCA2/BRM/BAF190B,
CC       SMARCA4/BRG1/BAF190A, SMARCB1/BAF47, SMARCC1/BAF155, SMARCE1/BAF57,
CC       SMARCC2/BAF170, PHF10/BAF45A, ACTL6A/BAF53A and actin. Component of
CC       neuron-specific chromatin remodeling complex (nBAF complex) composed of
CC       at least, ARID1A/BAF250A or ARID1B/BAF250B, SMARCD1/BAF60A,
CC       SMARCD3/BAF60C, SMARCA2/BRM/BAF190B, SMARCA4/BRG1/BAF190A,
CC       SMARCB1/BAF47, SMARCC1/BAF155, SMARCE1/BAF57, SMARCC2/BAF170,
CC       DPF1/BAF45B, DPF3/BAF45C, ACTL6B/BAF53B and actin (By similarity).
CC       Component of a SWI/SNF-like EBAFb complex, at least composed of
CC       SMARCA4/BRG1/BAF190A, SMARCB1/BAF47/SNF5, ACTL6A/BAF53A, SMARCE1/BAF57,
CC       SMARCD1/BAF60A, SMARCD2/BAF60B, SMARCC1/BAF155, SMARCC2/BAF170,
CC       ARID1B/BAF250B, MLLT1/ENL and actin (PubMed:12665591). Interacts
CC       through its C-terminus with SMARCA2/BRM/BAF190B and
CC       SMARCA4/BRG1/BAF190A (PubMed:12200431, PubMed:11988099,
CC       PubMed:15170388). Interacts with SMARCC1/BAF155 (PubMed:15170388).
CC       {ECO:0000250|UniProtKB:E9Q4N7, ECO:0000269|PubMed:11988099,
CC       ECO:0000269|PubMed:12200431, ECO:0000269|PubMed:12665591,
CC       ECO:0000269|PubMed:15170388, ECO:0000269|PubMed:18765789,
CC       ECO:0000303|PubMed:12672490, ECO:0000303|PubMed:22952240,
CC       ECO:0000303|PubMed:26601204}.
CC   -!- INTERACTION:
CC       Q8NFD5; P51531: SMARCA2; NbExp=3; IntAct=EBI-679921, EBI-679562;
CC       Q8NFD5; P51532: SMARCA4; NbExp=3; IntAct=EBI-679921, EBI-302489;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-ProRule:PRU00355,
CC       ECO:0000269|PubMed:11988099}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing, Alternative initiation; Named isoforms=4;
CC       Name=5;
CC         IsoId=Q8NFD5-5; Sequence=Displayed;
CC       Name=1;
CC         IsoId=Q8NFD5-1; Sequence=VSP_061510;
CC       Name=2;
CC         IsoId=Q8NFD5-2; Sequence=VSP_061511;
CC       Name=3;
CC         IsoId=Q8NFD5-3; Sequence=VSP_061512;
CC   -!- TISSUE SPECIFICITY: Widely expressed with high levels in heart,
CC       skeletal muscle and kidney. {ECO:0000269|PubMed:11988099,
CC       ECO:0000269|PubMed:12200431, ECO:0000269|PubMed:12665591}.
CC   -!- POLYMORPHISM: The poly-Gln region is polymorphic and the number of Gln
CC       varies in the population (from 17 to 23).
CC   -!- DISEASE: Coffin-Siris syndrome 1 (CSS1) [MIM:135900]: A form of Coffin-
CC       Siris syndrome, a congenital multiple malformation syndrome with broad
CC       phenotypic and genetic variability. Cardinal features are intellectual
CC       disability, coarse facial features, hypertrichosis, and hypoplastic or
CC       absent fifth digit nails or phalanges. Additional features include
CC       malformations of the cardiac, gastrointestinal, genitourinary, and/or
CC       central nervous systems. Sucking/feeding difficulties, poor growth,
CC       ophthalmologic abnormalities, hearing impairment, and spinal anomalies
CC       are common findings. Both autosomal dominant and autosomal recessive
CC       inheritance patterns have been reported. {ECO:0000269|PubMed:22405089,
CC       ECO:0000269|PubMed:22426308, ECO:0000269|PubMed:22426309}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- MISCELLANEOUS: [Isoform 1]: Produced by alternative initiation at Met-
CC       84 of isoform 5. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAG36928.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAL76077.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAN03447.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=AAN70985.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAN70985.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=CAA69592.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AL049820; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL162578; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL355297; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL591545; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AJ001216; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Y08266; CAA69592.1; ALT_FRAME; mRNA.
DR   EMBL; AF521671; AAN03447.1; ALT_FRAME; mRNA.
DR   EMBL; AF253515; AAN70985.1; ALT_SEQ; mRNA.
DR   EMBL; AF468300; AAL76077.1; ALT_INIT; mRNA.
DR   EMBL; AF259792; AAG36928.1; ALT_INIT; mRNA.
DR   EMBL; AB033061; BAA86549.1; -; mRNA.
DR   CCDS; CCDS5251.2; -. [Q8NFD5-5]
DR   CCDS; CCDS55072.2; -. [Q8NFD5-2]
DR   CCDS; CCDS87459.2; -. [Q8NFD5-3]
DR   RefSeq; NP_059989.2; NM_017519.2. [Q8NFD5-5]
DR   RefSeq; NP_065783.3; NM_020732.3.
DR   PDB; 2CXY; X-ray; 1.60 A; A=1124-1242.
DR   PDB; 2EH9; X-ray; 2.00 A; A=1124-1242.
DR   PDBsum; 2CXY; -.
DR   PDBsum; 2EH9; -.
DR   AlphaFoldDB; Q8NFD5; -.
DR   SMR; Q8NFD5; -.
DR   BioGRID; 121559; 150.
DR   ComplexPortal; CPX-1205; SWI/SNF ATP-dependent chromatin remodeling complex, ACTL6A-ARID1B-SMARCA2 variant.
DR   ComplexPortal; CPX-1206; SWI/SNF ATP-dependent chromatin remodeling complex, ACTL6A-ARID1B-SMARCA4 variant.
DR   ComplexPortal; CPX-1210; SWI/SNF ATP-dependent chromatin remodeling complex, ACTL6B-ARID1B-SMARCA2 variant.
DR   ComplexPortal; CPX-1211; SWI/SNF ATP-dependent chromatin remodeling complex, ACTL6B-ARID1B-SMARCA4 variant.
DR   ComplexPortal; CPX-1213; Neural progenitor-specific SWI/SNF ATP-dependent chromatin remodeling complex, ARID1B-SMARCA2 variant.
DR   ComplexPortal; CPX-1215; Neural progenitor-specific SWI/SNF ATP-dependent chromatin remodeling complex, ARID1B-SMARCA4 variant.
DR   ComplexPortal; CPX-1217; Neuron-specific SWI/SNF ATP-dependent chromatin remodeling complex, ARID1B-SMARCA2 variant.
DR   ComplexPortal; CPX-1218; Neuron-specific SWI/SNF ATP-dependent chromatin remodeling complex, ARID1B-SMARCA4 variant.
DR   ComplexPortal; CPX-1220; Brain-specific SWI/SNF ATP-dependent chromatin remodeling complex, ARID1B-SMARCA2 variant.
DR   ComplexPortal; CPX-1221; Brain-specific SWI/SNF ATP-dependent chromatin remodeling complex, ARID1B-SMARCA4 variant.
DR   ComplexPortal; CPX-1223; Muscle cell-specific SWI/SNF ATP-dependent chromatin remodeling complex, ACTL6A-ARID1B-SMARCA2 variant.
DR   ComplexPortal; CPX-1224; Muscle cell-specific SWI/SNF ATP-dependent chromatin remodeling complex, ACTL6A-ARID1B-SMARCA4 variant.
DR   ComplexPortal; CPX-1227; Muscle cell-specific SWI/SNF ATP-dependent chromatin remodeling complex, ACTL6B-ARID1B-SMARCA2 variant.
DR   ComplexPortal; CPX-1228; Muscle cell-specific SWI/SNF ATP-dependent chromatin remodeling complex, ACTL6B-ARID1B-SMARCA4 variant.
DR   CORUM; Q8NFD5; -.
DR   IntAct; Q8NFD5; 91.
DR   MINT; Q8NFD5; -.
DR   STRING; 9606.ENSP00000344546; -.
DR   GlyCosmos; Q8NFD5; 2 sites, 1 glycan.
DR   iPTMnet; Q8NFD5; -.
DR   PhosphoSitePlus; Q8NFD5; -.
DR   BioMuta; ARID1B; -.
DR   DMDM; 73921720; -.
DR   EPD; Q8NFD5; -.
DR   jPOST; Q8NFD5; -.
DR   MassIVE; Q8NFD5; -.
DR   MaxQB; Q8NFD5; -.
DR   PaxDb; Q8NFD5; -.
DR   PeptideAtlas; Q8NFD5; -.
DR   ProteomicsDB; 73289; -. [Q8NFD5-1]
DR   ProteomicsDB; 73290; -. [Q8NFD5-2]
DR   ProteomicsDB; 73291; -. [Q8NFD5-3]
DR   Antibodypedia; 19980; 186 antibodies from 27 providers.
DR   DNASU; 57492; -.
DR   Ensembl; ENST00000346085.10; ENSP00000344546.5; ENSG00000049618.25. [Q8NFD5-2]
DR   Ensembl; ENST00000350026.10; ENSP00000055163.7; ENSG00000049618.25. [Q8NFD5-1]
DR   Ensembl; ENST00000636930.2; ENSP00000490491.2; ENSG00000049618.25. [Q8NFD5-3]
DR   GeneID; 57492; -.
DR   KEGG; hsa:57492; -.
DR   MANE-Select; ENST00000636930.2; ENSP00000490491.2; NM_001374828.1; NP_001361757.1. [Q8NFD5-3]
DR   UCSC; uc003qqo.4; human. [Q8NFD5-5]
DR   AGR; HGNC:18040; -.
DR   CTD; 57492; -.
DR   DisGeNET; 57492; -.
DR   GeneCards; ARID1B; -.
DR   GeneReviews; ARID1B; -.
DR   HGNC; HGNC:18040; ARID1B.
DR   HPA; ENSG00000049618; Low tissue specificity.
DR   MalaCards; ARID1B; -.
DR   MIM; 135900; phenotype.
DR   MIM; 614556; gene.
DR   neXtProt; NX_Q8NFD5; -.
DR   OpenTargets; ENSG00000049618; -.
DR   Orphanet; 251056; 6q25 microdeletion syndrome.
DR   Orphanet; 1465; Coffin-Siris syndrome.
DR   PharmGKB; PA134909463; -.
DR   VEuPathDB; HostDB:ENSG00000049618; -.
DR   eggNOG; KOG2510; Eukaryota.
DR   GeneTree; ENSGT00940000155634; -.
DR   InParanoid; Q8NFD5; -.
DR   OMA; AHLPITR; -.
DR   PhylomeDB; Q8NFD5; -.
DR   TreeFam; TF320364; -.
DR   PathwayCommons; Q8NFD5; -.
DR   Reactome; R-HSA-3214858; RMTs methylate histone arginines.
DR   Reactome; R-HSA-8939243; RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known.
DR   SignaLink; Q8NFD5; -.
DR   SIGNOR; Q8NFD5; -.
DR   BioGRID-ORCS; 57492; 42 hits in 1196 CRISPR screens.
DR   ChiTaRS; ARID1B; human.
DR   EvolutionaryTrace; Q8NFD5; -.
DR   GeneWiki; ARID1B; -.
DR   GenomeRNAi; 57492; -.
DR   Pharos; Q8NFD5; Tbio.
DR   PRO; PR:Q8NFD5; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; Q8NFD5; protein.
DR   Bgee; ENSG00000049618; Expressed in bone marrow cell and 202 other tissues.
DR   ExpressionAtlas; Q8NFD5; baseline and differential.
DR   Genevisible; Q8NFD5; HS.
DR   GO; GO:0140092; C:bBAF complex; NAS:ComplexPortal.
DR   GO; GO:0035060; C:brahma complex; NAS:ComplexPortal.
DR   GO; GO:0000785; C:chromatin; NAS:ComplexPortal.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0071565; C:nBAF complex; IBA:GO_Central.
DR   GO; GO:0071564; C:npBAF complex; NAS:ComplexPortal.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0016514; C:SWI/SNF complex; IDA:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IDA:GDB.
DR   GO; GO:0003713; F:transcription coactivator activity; NAS:UniProtKB.
DR   GO; GO:1904385; P:cellular response to angiotensin; IEA:Ensembl.
DR   GO; GO:0006338; P:chromatin remodeling; NAS:ComplexPortal.
DR   GO; GO:0007399; P:nervous system development; IEA:UniProtKB-KW.
DR   GO; GO:0045597; P:positive regulation of cell differentiation; NAS:ComplexPortal.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; IBA:GO_Central.
DR   GO; GO:2000781; P:positive regulation of double-strand break repair; NAS:ComplexPortal.
DR   GO; GO:0045663; P:positive regulation of myoblast differentiation; NAS:ComplexPortal.
DR   GO; GO:0045582; P:positive regulation of T cell differentiation; NAS:ComplexPortal.
DR   GO; GO:0070316; P:regulation of G0 to G1 transition; NAS:ComplexPortal.
DR   GO; GO:2000045; P:regulation of G1/S transition of mitotic cell cycle; NAS:ComplexPortal.
DR   GO; GO:0030071; P:regulation of mitotic metaphase/anaphase transition; NAS:ComplexPortal.
DR   GO; GO:2000819; P:regulation of nucleotide-excision repair; NAS:ComplexPortal.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0002931; P:response to ischemia; IEA:Ensembl.
DR   GO; GO:0045815; P:transcription initiation-coupled chromatin remodeling; NAS:UniProtKB.
DR   CDD; cd16877; ARID_ARID1B; 1.
DR   Gene3D; 1.10.150.60; ARID DNA-binding domain; 1.
DR   InterPro; IPR038040; ARID_ARID1B.
DR   InterPro; IPR001606; ARID_dom.
DR   InterPro; IPR036431; ARID_dom_sf.
DR   InterPro; IPR021906; BAF250/Osa.
DR   InterPro; IPR033388; BAF250_C.
DR   PANTHER; PTHR12656:SF11; AT-RICH INTERACTIVE DOMAIN-CONTAINING PROTEIN 1B; 1.
DR   PANTHER; PTHR12656; BRG-1 ASSOCIATED FACTOR 250 BAF250; 1.
DR   Pfam; PF01388; ARID; 1.
DR   Pfam; PF12031; BAF250_C; 1.
DR   SMART; SM01014; ARID; 1.
DR   SMART; SM00501; BRIGHT; 1.
DR   SUPFAM; SSF46774; ARID-like; 1.
DR   PROSITE; PS51011; ARID; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative initiation; Alternative splicing;
KW   Chromatin regulator; DNA-binding; Intellectual disability; Methylation;
KW   Neurogenesis; Nucleus; Phosphoprotein; Reference proteome; Transcription;
KW   Transcription regulation; Triplet repeat expansion.
FT   CHAIN           1..2319
FT                   /note="AT-rich interactive domain-containing protein 1B"
FT                   /id="PRO_0000200576"
FT   DOMAIN          1136..1227
FT                   /note="ARID"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00355"
FT   REGION          1..74
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          155..306
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          321..414
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          486..546
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          577..1062
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1085..1129
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1230..1334
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1346..1443
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1475..1647
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1782..1852
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1904..1941
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1954..1973
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           502..506
FT                   /note="LXXLL"
FT   MOTIF           1441..1460
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000250|UniProtKB:O14497"
FT   MOTIF           2119..2123
FT                   /note="LXXLL"
FT   COMPBIAS        165..188
FT                   /note="Basic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        189..226
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        368..382
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        486..514
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        581..595
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        614..628
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        655..686
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        698..722
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        758..795
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        810..828
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        838..854
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        864..887
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        895..931
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        943..957
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        977..996
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1022..1062
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1097..1111
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1112..1128
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1242..1274
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1290..1332
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1363..1397
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1519..1534
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1577..1605
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1614..1645
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1796..1825
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1925..1941
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         487
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:E9Q4N7"
FT   MOD_RES         585
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         599
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         608
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:E9Q4N7"
FT   MOD_RES         640
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0007744|PubMed:24129315"
FT   MOD_RES         1625
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1638
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         1642
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         1798
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   MOD_RES         1860
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   VAR_SEQ         1..83
FT                   /note="Missing (in isoform 1)"
FT                   /id="VSP_061510"
FT   VAR_SEQ         662
FT                   /note="Q -> QDSGDATWKETFWL (in isoform 2)"
FT                   /id="VSP_061511"
FT   VAR_SEQ         1115
FT                   /note="K -> KDSYSSQGISQPPTPGNLPVPSPMSPSSASISSFHGDESDSISSPGW
FT                   PKTPSSP (in isoform 3)"
FT                   /id="VSP_061512"
FT   VARIANT         94
FT                   /note="A -> AA"
FT                   /evidence="ECO:0000269|PubMed:22405089"
FT                   /id="VAR_067662"
FT   VARIANT         128..130
FT                   /note="Missing"
FT                   /evidence="ECO:0000269|PubMed:22405089"
FT                   /id="VAR_067663"
FT   VARIANT         165
FT                   /note="Q -> H"
FT                   /evidence="ECO:0000269|PubMed:22405089"
FT                   /id="VAR_067664"
FT   VARIANT         329
FT                   /note="G -> S (in dbSNP:rs375160616)"
FT                   /evidence="ECO:0000269|PubMed:22405089"
FT                   /id="VAR_067665"
FT   VARIANT         401..402
FT                   /note="Missing"
FT                   /evidence="ECO:0000269|PubMed:22405089"
FT                   /id="VAR_067666"
FT   VARIANT         402
FT                   /note="Missing"
FT                   /evidence="ECO:0000269|PubMed:22405089"
FT                   /id="VAR_067667"
FT   VARIANT         410..411
FT                   /note="Missing"
FT                   /evidence="ECO:0000269|PubMed:22405089"
FT                   /id="VAR_067668"
FT   VARIANT         416..420
FT                   /note="Missing"
FT                   /evidence="ECO:0000269|PubMed:22405089"
FT                   /id="VAR_067669"
FT   VARIANT         446
FT                   /note="A -> V (in dbSNP:rs748273011)"
FT                   /evidence="ECO:0000269|PubMed:22405089"
FT                   /id="VAR_067670"
FT   VARIANT         479
FT                   /note="G -> A (in dbSNP:rs760718156)"
FT                   /evidence="ECO:0000269|PubMed:22405089"
FT                   /id="VAR_067671"
FT   VARIANT         512
FT                   /note="M -> V (in dbSNP:rs199948752)"
FT                   /evidence="ECO:0000269|PubMed:22405089"
FT                   /id="VAR_067672"
FT   VARIANT         533
FT                   /note="P -> PP"
FT                   /evidence="ECO:0000269|PubMed:22405089"
FT                   /id="VAR_067673"
FT   VARIANT         571
FT                   /note="P -> R (found in a patient with autism; unknown
FT                   pathological significance; dbSNP:rs769085274)"
FT                   /evidence="ECO:0000269|PubMed:26637798"
FT                   /id="VAR_078697"
FT   VARIANT         580
FT                   /note="S -> N (in dbSNP:rs764716697)"
FT                   /evidence="ECO:0000269|PubMed:22405089"
FT                   /id="VAR_067674"
FT   VARIANT         614
FT                   /note="M -> T (in dbSNP:rs141260832)"
FT                   /evidence="ECO:0000269|PubMed:22405089"
FT                   /id="VAR_067675"
FT   VARIANT         854
FT                   /note="S -> L (found in a patient with short stature;
FT                   unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:26376624"
FT                   /id="VAR_077456"
FT   VARIANT         897
FT                   /note="G -> A (in a breast cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036257"
FT   VARIANT         959
FT                   /note="Q -> E (in dbSNP:rs138254872)"
FT                   /evidence="ECO:0000269|PubMed:22405089"
FT                   /id="VAR_067676"
FT   VARIANT         1063
FT                   /note="Q -> L (in dbSNP:rs139620600)"
FT                   /evidence="ECO:0000269|PubMed:22405089"
FT                   /id="VAR_067677"
FT   VARIANT         1175
FT                   /note="V -> I (in dbSNP:rs775526039)"
FT                   /evidence="ECO:0000269|PubMed:22405089"
FT                   /id="VAR_067678"
FT   VARIANT         1332
FT                   /note="Q -> P (in dbSNP:rs768013849)"
FT                   /evidence="ECO:0000269|PubMed:22405089"
FT                   /id="VAR_067679"
FT   VARIANT         1354
FT                   /note="G -> E (in dbSNP:rs149389876)"
FT                   /evidence="ECO:0000269|PubMed:22405089"
FT                   /id="VAR_067680"
FT   VARIANT         1386
FT                   /note="G -> R (in dbSNP:rs199674889)"
FT                   /evidence="ECO:0000269|PubMed:22405089"
FT                   /id="VAR_067681"
FT   VARIANT         1404
FT                   /note="S -> N (in dbSNP:rs142808724)"
FT                   /evidence="ECO:0000269|PubMed:22405089"
FT                   /id="VAR_067682"
FT   VARIANT         1494
FT                   /note="P -> S"
FT                   /evidence="ECO:0000269|PubMed:22405089"
FT                   /id="VAR_067683"
FT   VARIANT         1496
FT                   /note="P -> S (found in a patient with autism; unknown
FT                   pathological significance; dbSNP:rs1051017338)"
FT                   /evidence="ECO:0000269|PubMed:26637798"
FT                   /id="VAR_078698"
FT   VARIANT         1519
FT                   /note="G -> A (probable disease-associated variant found in
FT                   a patient with short stature; de novo mutation)"
FT                   /evidence="ECO:0000269|PubMed:26376624"
FT                   /id="VAR_077457"
FT   VARIANT         1549
FT                   /note="Q -> K"
FT                   /evidence="ECO:0000269|PubMed:22405089"
FT                   /id="VAR_067684"
FT   VARIANT         1589
FT                   /note="R -> H (in dbSNP:rs1449208173)"
FT                   /evidence="ECO:0000269|PubMed:22405089"
FT                   /id="VAR_067685"
FT   VARIANT         1646
FT                   /note="P -> L (found in a patient with short stature;
FT                   unknown pathological significance; dbSNP:rs1455506883)"
FT                   /evidence="ECO:0000269|PubMed:26376624"
FT                   /id="VAR_077458"
FT   VARIANT         1656
FT                   /note="T -> M (in dbSNP:rs777745107)"
FT                   /evidence="ECO:0000269|PubMed:22405089"
FT                   /id="VAR_067686"
FT   VARIANT         1742
FT                   /note="N -> S (in dbSNP:rs140177120)"
FT                   /evidence="ECO:0000269|PubMed:22405089"
FT                   /id="VAR_067687"
FT   VARIANT         1816
FT                   /note="Missing"
FT                   /evidence="ECO:0000269|PubMed:22405089"
FT                   /id="VAR_067688"
FT   VARIANT         1856
FT                   /note="K -> R (in dbSNP:rs574141489)"
FT                   /evidence="ECO:0000269|PubMed:22405089"
FT                   /id="VAR_067689"
FT   VARIANT         1934
FT                   /note="D -> N (in dbSNP:rs200305796)"
FT                   /evidence="ECO:0000269|PubMed:22405089"
FT                   /id="VAR_067690"
FT   VARIANT         1981
FT                   /note="K -> R (in dbSNP:rs758204258)"
FT                   /evidence="ECO:0000269|PubMed:22405089"
FT                   /id="VAR_067691"
FT   VARIANT         2037
FT                   /note="K -> R (in dbSNP:rs756220726)"
FT                   /evidence="ECO:0000269|PubMed:22405089"
FT                   /id="VAR_067692"
FT   VARIANT         2070
FT                   /note="D -> Y (probable disease-associated variant found in
FT                   a patient with short stature; de novo mutation)"
FT                   /evidence="ECO:0000269|PubMed:26376624"
FT                   /id="VAR_077459"
FT   VARIANT         2246
FT                   /note="Q -> R"
FT                   /evidence="ECO:0000269|PubMed:22405089"
FT                   /id="VAR_067693"
FT   CONFLICT        353
FT                   /note="S -> N (in Ref. 5; AAN70985)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        417..419
FT                   /note="AGA -> SRS (in Ref. 4; AAN03447)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        529
FT                   /note="P -> A (in Ref. 5; AAN70985)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        770
FT                   /note="V -> A (in Ref. 6; AAL76077)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        987
FT                   /note="T -> P (in Ref. 6; AAL76077)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1284
FT                   /note="T -> I (in Ref. 7; AAG36928)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1422
FT                   /note="P -> S (in Ref. 5; AAN70985)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1515
FT                   /note="P -> L (in Ref. 8; BAA86549)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1617
FT                   /note="P -> S (in Ref. 5; AAN70985)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1796
FT                   /note="D -> N (in Ref. 6; AAL76077)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2279
FT                   /note="D -> N (in Ref. 7; AAG36928)"
FT                   /evidence="ECO:0000305"
FT   HELIX           1129..1132
FT                   /evidence="ECO:0007829|PDB:2CXY"
FT   HELIX           1139..1153
FT                   /evidence="ECO:0007829|PDB:2CXY"
FT   HELIX           1170..1180
FT                   /evidence="ECO:0007829|PDB:2CXY"
FT   HELIX           1183..1189
FT                   /evidence="ECO:0007829|PDB:2CXY"
FT   HELIX           1192..1198
FT                   /evidence="ECO:0007829|PDB:2CXY"
FT   HELIX           1205..1218
FT                   /evidence="ECO:0007829|PDB:2CXY"
FT   HELIX           1220..1228
FT                   /evidence="ECO:0007829|PDB:2CXY"
FT   INIT_MET        Q8NFD5-1:1
FT                   /note="Removed"
FT                   /evidence="ECO:0007744|PubMed:19413330"
FT   MOD_RES         Q8NFD5-1:2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0007744|PubMed:19413330"
SQ   SEQUENCE   2319 AA;  243943 MW;  0267747AF33071BF CRC64;
     MAARAAAAAA AAAARARARA GSGERRAPPG PRPAPGARDL EAGARGAAAA AAAPGPMLGG
     GGDGGGGLNS VHHHPLLPRH ELNMAHNAGA AAAAGTHSAK SGGSEAALKE GGSAAALSSS
     SSSSAAAAAA SSSSSSGPGS AMETGLLPNH KLKTVGEAPA APPHQQHHHH HHAHHHHHHA
     HHLHHHHALQ QQLNQFQQQQ QQQQQQQQQQ QQQQHPISNN NSLGGAGGGA PQPGPDMEQP
     QHGGAKDSAA GGQADPPGPP LLSKPGDEDD APPKMGEPAG GRYEHPGLGA LGTQQPPVAV
     PGGGGGPAAV PEFNNYYGSA APASGGPGGR AGPCFDQHGG QQSPGMGMMH SASAAAAGAP
     GSMDPLQNSH EGYPNSQCNH YPGYSRPGAG GGGGGGGGGG GGSGGGGGGG GAGAGGAGAG
     AVAAAAAAAA AAAGGGGGGG YGGSSAGYGV LSSPRQQGGG MMMGPGGGGA ASLSKAAAGS
     AAGGFQRFAG QNQHPSGATP TLNQLLTSPS PMMRSYGGSY PEYSSPSAPP PPPSQPQSQA
     AAAGAAAGGQ QAAAGMGLGK DMGAQYAAAS PAWAAAQQRS HPAMSPGTPG PTMGRSQGSP
     MDPMVMKRPQ LYGMGSNPHS QPQQSSPYPG GSYGPPGPQR YPIGIQGRTP GAMAGMQYPQ
     QQMPPQYGQQ GVSGYCQQGQ QPYYSQQPQP PHLPPQAQYL PSQSQQRYQP QQDMSQEGYG
     TRSQPPLAPG KPNHEDLNLI QQERPSSLPD LSGSIDDLPT GTEATLSSAV SASGSTSSQG
     DQSNPAQSPF SPHASPHLSS IPGGPSPSPV GSPVGSNQSR SGPISPASIP GSQMPPQPPG
     SQSESSSHPA LSQSPMPQER GFMAGTQRNP QMAQYGPQQT GPSMSPHPSP GGQMHAGISS
     FQQSNSSGTY GPQMSQYGPQ GNYSRPPAYS GVPSASYSGP GPGMGISANN QMHGQGPSQP
     CGAVPLGRMP SAGMQNRPFP GNMSSMTPSS PGMSQQGGPG MGPPMPTVNR KAQEAAAAVM
     QAAANSAQSR QGSFPGMNQS GLMASSSPYS QPMNNSSSLM NTQAPPYSMA PAMVNSSAAS
     VGLADMMSPG ESKLPLPLKA DGKEEGTPQP ESKSKKSSSS TTTGEKITKV YELGNEPERK
     LWVDRYLTFM EERGSPVSSL PAVGKKPLDL FRLYVCVKEI GGLAQVNKNK KWRELATNLN
     VGTSSSAASS LKKQYIQYLF AFECKIERGE EPPPEVFSTG DTKKQPKLQP PSPANSGSLQ
     GPQTPQSTGS NSMAEVPGDL KPPTPASTPH GQMTPMQGGR SSTISVHDPF SDVSDSSFPK
     RNSMTPNAPY QQGMSMPDVM GRMPYEPNKD PFGGMRKVPG SSEPFMTQGQ MPNSSMQDMY
     NQSPSGAMSN LGMGQRQQFP YGASYDRRHE PYGQQYPGQG PPSGQPPYGG HQPGLYPQQP
     NYKRHMDGMY GPPAKRHEGD MYNMQYSSQQ QEMYNQYGGS YSGPDRRPIQ GQYPYPYSRE
     RMQGPGQIQT HGIPPQMMGG PLQSSSSEGP QQNMWAARND MPYPYQNRQG PGGPTQAPPY
     PGMNRTDDMM VPDQRINHES QWPSHVSQRQ PYMSSSASMQ PITRPPQPSY QTPPSLPNHI
     SRAPSPASFQ RSLENRMSPS KSPFLPSMKM QKVMPTVPTS QVTGPPPQPP PIRREITFPP
     GSVEASQPVL KQRRKITSKD IVTPEAWRVM MSLKSGLLAE STWALDTINI LLYDDSTVAT
     FNLSQLSGFL ELLVEYFRKC LIDIFGILME YEVGDPSQKA LDHNAARKDD SQSLADDSGK
     EEEDAECIDD DEEDEEDEEE DSEKTESDEK SSIALTAPDA AADPKEKPKQ ASKFDKLPIK
     IVKKNNLFVV DRSDKLGRVQ EFNSGLLHWQ LGGGDTTEHI QTHFESKMEI PPRRRPPPPL
     SSAGRKKEQE GKGDSEEQQE KSIIATIDDV LSARPGALPE DANPGPQTES SKFPFGIQQA
     KSHRNIKLLE DEPRSRDETP LCTIAHWQDS LAKRCICVSN IVRSLSFVPG NDAEMSKHPG
     LVLILGKLIL LHHEHPERKR APQTYEKEED EDKGVACSKD EWWWDCLEVL RDNTLVTLAN
     ISGQLDLSAY TESICLPILD GLLHWMVCPS AEAQDPFPTV GPNSVLSPQR LVLETLCKLS
     IQDNNVDLIL ATPPFSRQEK FYATLVRYVG DRKNPVCREM SMALLSNLAQ GDALAARAIA
     VQKGSIGNLI SFLEDGVTMA QYQQSQHNLM HMQPPPLEPP SVDMMCRAAK ALLAMARVDE
     NRSEFLLHEG RLLDISISAV LNSLVASVIC DVLFQIGQL
//
